Single User License
INR 135120
Site License
INR 270240
Corporate User License
INR 405360

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Ulcerative Colitis-Pipeline Review, H1 2015

Ulcerative Colitis-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Ulcerative Colitis-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Ulcerative Colitis-Pipeline Review, H1 2015', provides an overview of the Ulcerative Colitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ulcerative Colitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ulcerative Colitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Ulcerative Colitis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Ulcerative Colitis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Ulcerative Colitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Ulcerative Colitis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Ulcerative Colitis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Ulcerative Colitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Ulcerative Colitis Overview 11

Therapeutics Development 12

Pipeline Products for Ulcerative Colitis-Overview 12

Pipeline Products for Ulcerative Colitis-Comparative Analysis 13

Ulcerative Colitis-Therapeutics under Development by Companies 14

Ulcerative Colitis-Therapeutics under Investigation by Universities/Institutes 21

Ulcerative Colitis-Pipeline Products Glance 22

Late Stage Products 22

Clinical Stage Products 23

Early Stage Products 24

Unknown Stage Products 25

Ulcerative Colitis-Products under Development by Companies 26

Ulcerative Colitis-Products under Investigation by Universities/Institutes 33

Ulcerative Colitis-Companies Involved in Therapeutics Development 34

Ajinomoto Pharmaceuticals Co., Ltd. 34

AlphaMab Co., Ltd 35

Altheus Therapeutics, Inc. 36

Am-Pharma B.V. 37

Amgen Inc. 38

Astellas Pharma Inc. 39

AstraZeneca PLC 40

Athersys, Inc. 41

Atlantic Healthcare plc 42

Avaxia Biologics, Inc. 43

Biocon Limited 44

BioLineRx, Ltd. 45

Bristol-Myers Squibb Company 46

Celgene Corporation 47

Cellceutix Corporation 48

Celltrion, Inc. 49

ChemoCentryx, Inc. 50

ChironWells GmbH 51

Cosmo Pharmaceuticals S.p.A 52

Dr. Falk Pharma GmbH 53

Drais Pharmaceuticals, Inc. 54

Effimune SAS 55

Emergent BioSolutions Inc. 56

Enceladus Pharmaceuticals BV 57

Epirus Biopharmaceuticals, Inc. 58

Euroscreen S.A. 59

Farmacija d.o.o. Tuzla 60

Flexion Therapeutics, Inc. 61

Galapagos NV 62

Genentech, Inc. 63

Genfit SA 64

Genor BioPharma Co., Ltd. 65

Gilead Sciences, Inc. 66

GT Biologics Limited 67

GW Pharmaceuticals plc 68

iCo Therapeutics Inc. 69

InDex Pharmaceuticals AB 70

INOXIA Lifesciences GmbH 71

Invion Limited 72

Johnson & Johnson 73

Kaken Pharmaceutical Co., Ltd. 74

LIPID THERAPEUTICS GmbH 75

LTT Bio-Pharma Co., Ltd. 76

Mabion SA 77

Medestea Research & Production S.p.A. 78

Morphotek, Inc. 79

Nogra Pharma Limited 80

Oncobiologics, Inc. 81

Pfizer Inc. 82

Pluristem Therapeutics Inc. 83

ProtAb Ltd 84

Qu Biologics Inc. 85

Receptos, Inc. 86

Sandoz Inc. 87

Sanofi 88

Sigmoid Pharma Limited 89

Stelic Institute & Co. 90

sterna biologicals Gmbh & Co KG 91

Synergy Pharmaceuticals, Inc. 92

Takeda Pharmaceutical Company Limited 93

TiGenix NV 94

Tillotts Pharma AG 95

Trino Therapeutics Ltd 96

Vascular Biogenics Ltd. 97

Ventria Bioscience 98

Zyngenia, Inc. 99

Ulcerative Colitis-Therapeutics Assessment 100

Assessment by Monotherapy Products 100

Assessment by Combination Products 101

Assessment by Target 102

Assessment by Mechanism of Action 106

Assessment by Route of Administration 109

Assessment by Molecule Type 111

Drug Profiles 113

(mesalamine + N-acetylcysteine)-Drug Profile 113

(metenkefalin + tridecactide)-Drug Profile 115

AB-0045-Drug Profile 116

abrilumab-Drug Profile 117

ABS-11-Drug Profile 119

adalimumab biosimilar-Drug Profile 120

adalimumab biosimilar-Drug Profile 122

adalimumab biosimilar-Drug Profile 123

adalimumab biosimilar-Drug Profile 124

adalimumab biosimilar-Drug Profile 125

adalimumab biosimilar-Drug Profile 126

adalimumab biosimilar-Drug Profile 127

adalimumab biosimilar-Drug Profile 128

AJM-300-Drug Profile 129

alicaforsen sodium-Drug Profile 131

Anatabine-Drug Profile 132

apremilast-Drug Profile 133

ASP-3291-Drug Profile 136

AVX-470-Drug Profile 137

AW/EPO-002-Drug Profile 138

AW/EPO-003-Drug Profile 139

AW/EPOPD-01-Drug Profile 140

AW/EPOPD-02-Drug Profile 141

AW/EPOPD-06-Drug Profile 142

bertilimumab-Drug Profile 143

BL-7040-Drug Profile 145

BLI-1006-Drug Profile 148

brilacidin-Drug Profile 149

budesonide-Drug Profile 151

budesonide ER-Drug Profile 154

budesonide ER-Drug Profile 156

CCX-507-Drug Profile 157

Cell Therapy for Ulcerative Colitis and Inflammatory Bowel Disease-Drug Profile 158

CNDO-201-Drug Profile 159

Cx-602-Drug Profile 161

cyclosporine CR-Drug Profile 162

DIMS-0150-Drug Profile 163

Drugs for Ulcerative Colitis-Drug Profile 165

eldelumab-Drug Profile 166

enalaprilat-Drug Profile 168

ES-210-Drug Profile 169

ESN-282-Drug Profile 170

etrolizumab-Drug Profile 171

FX-003-Drug Profile 173

GED-0507-Drug Profile 174

GFT-505-Drug Profile 175

GLPG-0974-Drug Profile 178

GLPG-1205-Drug Profile 179

GS-5745-Drug Profile 180

GWP-42003-Drug Profile 181

hyaluronate sodium-Drug Profile 183

IAC VITA-Drug Profile 184

infliximab-Drug Profile 186

infliximab biosimilar-Drug Profile 188

infliximab biosimilar-Drug Profile 190

infliximab biosimilar-Drug Profile 191

infliximab biosimilar-Drug Profile 192

INV-103-Drug Profile 193

INV-88-Drug Profile 195

KAG-308-Drug Profile 196

KANAb-071-Drug Profile 197

Leukothera-Drug Profile 198

Low Molecular Weight Heparin-Drug Profile 199

LT-0011-Drug Profile 200

LT-02-Drug Profile 201

MD-707-Drug Profile 202

mesalamine-Drug Profile 203

mesalamine-Drug Profile 204

mesalamine CR-Drug Profile 205

mesalamine ER-Drug Profile 206

Monoclonal Antibodies to Antagonize Metallothioneins for Ulcerative Colitis and Crohn's Disease-Drug Profile 208

Monoclonal Antibodies to Inhibit TNFR25 for Gastrointestinal Disorders and Asthma-Drug Profile 210

Monoclonal Antibody to Inhibit Ang-2 and TNF-a for Ulcerative Colitis, Arthritis and Inflammatory Disease-Drug Profile 211

Monoclonal Antibody to Inhibit CD3 for Autoimmune Disorders, CNS Disorders, Infectious Diseases, Liver Diseases, Metabolic Disorders and Cardiovascular Diseases-Drug Profile 212

MultiStem-Drug Profile 214

naltrexone-Drug Profile 217

Nanocort-Drug Profile 218

peficitinib-Drug Profile 220

Peptides to Inhibit IL-1 Beta for Ulcerative Colitis and Crohn's Disease-Drug Profile 222

PF-00547659-Drug Profile 223

PH-44-Drug Profile 225

PH-46A-Drug Profile 226

PH-5-Drug Profile 227

Prozumab-Drug Profile 228

QBECO-Drug Profile 229

Recombinant Human Alkaline Phosphatase-Drug Profile 231

Rosburix-Drug Profile 233

RPC-1063-Drug Profile 234

SAR-252067-Drug Profile 236

SB-012-Drug Profile 237

SD-010-Drug Profile 238

Small Molecule for Ulcerative Colitis and Inflammation-Drug Profile 239

Small Molecule to Agonize OP3 Receptor for Crohn's Disease and Ulcerative Colitis-Drug Profile 240

Small Molecules for Gastrointestinal Disorders-Drug Profile 241

Small Molecules to Inhibit IL-13 for Ulcerative Colitis-Drug Profile 242

Small Molecules to Target IL-13 for Ulcerative Colitis-Drug Profile 243

SP-333-Drug Profile 244

Stem Cell Therapy for Inflammatory Bowel Disease-Drug Profile 245

STNM-01-Drug Profile 246

TAK-114-Drug Profile 247

tofacitinib-Drug Profile 249

TP-10-Drug Profile 253

VB-201-Drug Profile 254

VEDA-1209-Drug Profile 256

vedolizumab-Drug Profile 257

VEN-120-Drug Profile 259

Ulcerative Colitis-Recent Pipeline Updates 260

Ulcerative Colitis-Dormant Projects 337

Ulcerative Colitis-Discontinued Products 340

Ulcerative Colitis-Product Development Milestones 342

Featured News & Press Releases 342

Appendix 350

Methodology 350

Coverage 350

Secondary Research 350

Primary Research 350

Expert Panel Validation 350

Contact Us 351

Disclaimer 351

List of Tables

Number of Products under Development for Ulcerative Colitis, H1 2015 20

Number of Products under Development for Ulcerative Colitis-Comparative Analysis, H1 2015 21

Number of Products under Development by Companies, H1 2015 23

Number of Products under Development by Companies, H1 2015 (Contd..1) 24

Number of Products under Development by Companies, H1 2015 (Contd..2) 25

Number of Products under Development by Companies, H1 2015 (Contd..3) 26

Number of Products under Development by Companies, H1 2015 (Contd..4) 27

Number of Products under Development by Companies, H1 2015 (Contd..5) 28

Number of Products under Investigation by Universities/Institutes, H1 2015 29

Comparative Analysis by Late Stage Development, H1 2015 30

Comparative Analysis by Clinical Stage Development, H1 2015 31

Comparative Analysis by Early Stage Development, H1 2015 32

Comparative Analysis by Unknown Stage Development, H1 2015 33

Products under Development by Companies, H1 2015 34

Products under Development by Companies, H1 2015 (Contd..1) 35

Products under Development by Companies, H1 2015 (Contd..2) 36

Products under Development by Companies, H1 2015 (Contd..3) 37

Products under Development by Companies, H1 2015 (Contd..4) 38

Products under Development by Companies, H1 2015 (Contd..5) 39

Products under Development by Companies, H1 2015 (Contd..6) 40

Products under Investigation by Universities/Institutes, H1 2015 41

Ulcerative Colitis-Pipeline by Ajinomoto Pharmaceuticals Co., Ltd., H1 2015 42

Ulcerative Colitis-Pipeline by AlphaMab Co., Ltd, H1 2015 43

Ulcerative Colitis-Pipeline by Altheus Therapeutics, Inc., H1 2015 44

Ulcerative Colitis-Pipeline by Am-Pharma B.V., H1 2015 45

Ulcerative Colitis-Pipeline by Amgen Inc., H1 2015 46

Ulcerative Colitis-Pipeline by Astellas Pharma Inc., H1 2015 47

Ulcerative Colitis-Pipeline by AstraZeneca PLC, H1 2015 48

Ulcerative Colitis-Pipeline by Athersys, Inc., H1 2015 49

Ulcerative Colitis-Pipeline by Atlantic Healthcare plc, H1 2015 50

Ulcerative Colitis-Pipeline by Avaxia Biologics, Inc., H1 2015 51

Ulcerative Colitis-Pipeline by Biocon Limited, H1 2015 52

Ulcerative Colitis-Pipeline by BioLineRx, Ltd., H1 2015 53

Ulcerative Colitis-Pipeline by Bristol-Myers Squibb Company, H1 2015 54

Ulcerative Colitis-Pipeline by Celgene Corporation, H1 2015 55

Ulcerative Colitis-Pipeline by Cellceutix Corporation, H1 2015 56

Ulcerative Colitis-Pipeline by Celltrion, Inc., H1 2015 57

Ulcerative Colitis-Pipeline by ChemoCentryx, Inc., H1 2015 58

Ulcerative Colitis-Pipeline by ChironWells GmbH, H1 2015 59

Ulcerative Colitis-Pipeline by Cosmo Pharmaceuticals S.p.A, H1 2015 60

Ulcerative Colitis-Pipeline by Dr. Falk Pharma GmbH, H1 2015 61

Ulcerative Colitis-Pipeline by Drais Pharmaceuticals, Inc., H1 2015 62

Ulcerative Colitis-Pipeline by Effimune SAS, H1 2015 63

Ulcerative Colitis-Pipeline by Emergent BioSolutions Inc., H1 2015 64

Ulcerative Colitis-Pipeline by Enceladus Pharmaceuticals BV, H1 2015 65

Ulcerative Colitis-Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015 66

Ulcerative Colitis-Pipeline by Euroscreen S.A., H1 2015 67

Ulcerative Colitis-Pipeline by Farmacija d.o.o. Tuzla, H1 2015 68

Ulcerative Colitis-Pipeline by Flexion Therapeutics, Inc., H1 2015 69

Ulcerative Colitis-Pipeline by Galapagos NV, H1 2015 70

Ulcerative Colitis-Pipeline by Genentech, Inc., H1 2015 71

Ulcerative Colitis-Pipeline by Genfit SA, H1 2015 72

Ulcerative Colitis-Pipeline by Genor BioPharma Co., Ltd., H1 2015 73

Ulcerative Colitis-Pipeline by Gilead Sciences, Inc., H1 2015 74

Ulcerative Colitis-Pipeline by GT Biologics Limited, H1 2015 75

Ulcerative Colitis-Pipeline by GW Pharmaceuticals plc, H1 2015 76

Ulcerative Colitis-Pipeline by iCo Therapeutics Inc., H1 2015 77

Ulcerative Colitis-Pipeline by InDex Pharmaceuticals AB, H1 2015 78

Ulcerative Colitis-Pipeline by INOXIA Lifesciences GmbH, H1 2015 79

Ulcerative Colitis-Pipeline by Invion Limited, H1 2015 80

Ulcerative Colitis-Pipeline by Johnson & Johnson, H1 2015 81

Ulcerative Colitis-Pipeline by Kaken Pharmaceutical Co., Ltd., H1 2015 82

Ulcerative Colitis-Pipeline by LIPID THERAPEUTICS GmbH, H1 2015 83

Ulcerative Colitis-Pipeline by LTT Bio-Pharma Co., Ltd., H1 2015 84

Ulcerative Colitis-Pipeline by Mabion SA, H1 2015 85

Ulcerative Colitis-Pipeline by Medestea Research & Production S.p.A., H1 2015 86

Ulcerative Colitis-Pipeline by Morphotek, Inc., H1 2015 87

Ulcerative Colitis-Pipeline by Nogra Pharma Limited, H1 2015 88

Ulcerative Colitis-Pipeline by Oncobiologics, Inc., H1 2015 89

Ulcerative Colitis-Pipeline by Pfizer Inc., H1 2015 90

Ulcerative Colitis-Pipeline by Pluristem Therapeutics Inc., H1 2015 91

Ulcerative Colitis-Pipeline by ProtAb Ltd, H1 2015 92

Ulcerative Colitis-Pipeline by Qu Biologics Inc., H1 2015 93

Ulcerative Colitis-Pipeline by Receptos, Inc., H1 2015 94

Ulcerative Colitis-Pipeline by Sandoz Inc., H1 2015 95

Ulcerative Colitis-Pipeline by Sanofi, H1 2015 96

Ulcerative Colitis-Pipeline by Sigmoid Pharma Limited, H1 2015 97

Ulcerative Colitis-Pipeline by Stelic Institute & Co., H1 2015 98

Ulcerative Colitis-Pipeline by sterna biologicals Gmbh & Co KG, H1 2015 99

Ulcerative Colitis-Pipeline by Synergy Pharmaceuticals, Inc., H1 2015 100

Ulcerative Colitis-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 101

Ulcerative Colitis-Pipeline by TiGenix NV, H1 2015 102

Ulcerative Colitis-Pipeline by Tillotts Pharma AG, H1 2015 103

Ulcerative Colitis-Pipeline by Trino Therapeutics Ltd, H1 2015 104

Ulcerative Colitis-Pipeline by Vascular Biogenics Ltd., H1 2015 105

Ulcerative Colitis-Pipeline by Ventria Bioscience, H1 2015 106

Ulcerative Colitis-Pipeline by Zyngenia, Inc., H1 2015 107

Assessment by Monotherapy Products, H1 2015 108

Assessment by Combination Products, H1 2015 109

Number of Products by Stage and Target, H1 2015 111

Number of Products by Stage and Mechanism of Action, H1 2015 115

Number of Products by Stage and Route of Administration, H1 2015 118

Number of Products by Stage and Molecule Type, H1 2015 120

Ulcerative Colitis Therapeutics-Recent Pipeline Updates, H1 2015 268

Ulcerative Colitis-Dormant Projects, H1 2015 345

Ulcerative Colitis-Discontinued Products, H1 2015 348

Ulcerative Colitis-Discontinued Products (Contd..1), H1 2015 349

List of Figures

Number of Products under Development for Ulcerative Colitis, H1 2015 20

Number of Products under Development for Ulcerative Colitis-Comparative Analysis, H1 2015 21

Number of Products under Development by Companies, H1 2015 22

Comparative Analysis by Late Stage Development, H1 2015 30

Comparative Analysis by Clinical Stage Development, H1 2015 31

Comparative Analysis by Early Stage Products, H1 2015 32

Assessment by Monotherapy Products, H1 2015 108

Assessment by Combination Products, H1 2015 109

Number of Products by Top 10 Targets, H1 2015 110

Number of Products by Stage and Top 10 Targets, H1 2015 110

Number of Products by Top 10 Mechanism of Actions, H1 2015 114

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 114

Number of Products by Top 10 Routes of Administration, H1 2015 117

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 117

Number of Products by Top 10 Molecule Types, H1 2015 119

Number of Products by Stage and Top 10 Molecule Types, H1 2015 119

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Ajinomoto Pharmaceuticals Co., Ltd.

AlphaMab Co., Ltd

Altheus Therapeutics, Inc.

Am-Pharma B.V.

Amgen Inc.

Astellas Pharma Inc.

AstraZeneca PLC

Athersys, Inc.

Atlantic Healthcare plc

Avaxia Biologics, Inc.

Biocon Limited

BioLineRx, Ltd.

Bristol-Myers Squibb Company

Celgene Corporation

Cellceutix Corporation

Celltrion, Inc.

ChemoCentryx, Inc.

ChironWells GmbH

Cosmo Pharmaceuticals S.p.A

Dr. Falk Pharma GmbH

Drais Pharmaceuticals, Inc.

Effimune SAS

Emergent BioSolutions Inc.

Enceladus Pharmaceuticals BV

Epirus Biopharmaceuticals, Inc.

Euroscreen S.A.

Farmacija d.o.o. Tuzla

Flexion Therapeutics, Inc.

Galapagos NV

Genentech, Inc.

Genfit SA

Genor BioPharma Co., Ltd.

Gilead Sciences, Inc.

GT Biologics Limited

GW Pharmaceuticals plc

iCo Therapeutics Inc.

InDex Pharmaceuticals AB

INOXIA Lifesciences GmbH

Invion Limited

Johnson & Johnson

Kaken Pharmaceutical Co., Ltd.

LIPID THERAPEUTICS GmbH

LTT Bio-Pharma Co., Ltd.

Mabion SA

Medestea Research & Production S.p.A.

Morphotek, Inc.

Nogra Pharma Limited

Oncobiologics, Inc.

Pfizer Inc.

Pluristem Therapeutics Inc.

ProtAb Ltd

Qu Biologics Inc.

Receptos, Inc.

Sandoz Inc.

Sanofi

Sigmoid Pharma Limited

Stelic Institute & Co.

sterna biologicals Gmbh & Co KG

Synergy Pharmaceuticals, Inc.

Takeda Pharmaceutical Company Limited

TiGenix NV

Tillotts Pharma AG

Trino Therapeutics Ltd

Vascular Biogenics Ltd.

Ventria Bioscience

Zyngenia, Inc.

Ulcerative Colitis Therapeutic Products under Development, Key Players in Ulcerative Colitis Therapeutics, Ulcerative Colitis Pipeline Overview, Ulcerative Colitis Pipeline, Ulcerative Colitis Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com